Literature DB >> 18538422

Glutathione: a novel treatment target in psychiatry.

Michael Berk1, Felicity Ng, Olivia Dean, Seetal Dodd, Ashley I Bush.   

Abstract

There is accumulating evidence for oxidative stress mechanisms as common pathophysiological pathways in diverse psychiatric disorders, which offers novel treatment targets in oxidation biology systems. Of these the glutathione system has the most favourable theoretical foundation, given its dominance as the most generic of cellular antioxidants. Clinically, this hypothesis has been supported by several recently published studies that have reported on the efficacy of N-acetylcysteine, a glutathione precursor, in the treatment of various psychiatric disorders. This article outlines the multidimensional evidence that currently exists for oxidative stress mechanisms in psychiatric disorders and specifically discusses glutathione as a promising novel therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538422     DOI: 10.1016/j.tips.2008.05.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  41 in total

1.  Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism.

Authors:  Stepan Melnyk; George J Fuchs; Eldon Schulz; Maya Lopez; Stephen G Kahler; Jill J Fussell; Jayne Bellando; Oleksandra Pavliv; Shannon Rose; Lisa Seidel; David W Gaylor; S Jill James
Journal:  J Autism Dev Disord       Date:  2012-03

2.  N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study.

Authors:  Eduardo Prado; Michael Maes; Luiz Gustavo Piccoli; Marcela Baracat; Décio Sabattini Barbosa; Olavo Franco; Seetal Dodd; Michael Berk; Sandra Odebrecht Vargas Nunes
Journal:  Redox Rep       Date:  2015-03-02       Impact factor: 4.412

Review 3.  Stage managing bipolar disorder.

Authors:  Michael Berk; Lesley Berk; Seetal Dodd; Sue Cotton; Craig Macneil; Rothanthi Daglas; Philippe Conus; Andreas Bechdolf; Steven Moylan; Gin S Malhi
Journal:  Bipolar Disord       Date:  2013-06-20       Impact factor: 6.744

Review 4.  Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Authors:  George Anderson; Michael Berk; Olivia Dean; Steven Moylan; Michael Maes
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 5.  Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia.

Authors:  Michael J Berridge
Journal:  Prion       Date:  2012-08-16       Impact factor: 3.931

6.  Peripheral antioxidant markers are associated with total hippocampal and CA3/dentate gyrus volume in MDD and healthy controls-preliminary findings.

Authors:  Daniel Lindqvist; Susanne Mueller; Synthia H Mellon; Yali Su; Elissa S Epel; Victor I Reus; Rebecca Rosser; Laura Mahan; R Scott Mackin; Tony T Yang; Owen M Wolkowitz
Journal:  Psychiatry Res       Date:  2014-09-16       Impact factor: 3.222

7.  Biomarkers and clinical staging in psychiatry.

Authors:  Patrick McGorry; Matcheri Keshavan; Sherilyn Goldstone; Paul Amminger; Kelly Allott; Michael Berk; Suzie Lavoie; Christos Pantelis; Alison Yung; Stephen Wood; Ian Hickie
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

Review 8.  Potential role of N-acetylcysteine in the management of substance use disorders.

Authors:  Erin A McClure; Cassandra D Gipson; Robert J Malcolm; Peter W Kalivas; Kevin M Gray
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

9.  Clinical relevance of tag single nucleotide polymorphisms within the CAT gene in patients with PTSD in the Chongqing Han population.

Authors:  Zhao-Xia Duan; Wei Li; Jian-Yi Kang; Jie-Yuan Zhang; Kui-Jun Chen; Bing-Cang Li; Mei He; Jian-Min Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 10.  Potential mechanisms of action of lithium in bipolar disorder. Current understanding.

Authors:  Gin S Malhi; Michelle Tanious; Pritha Das; Carissa M Coulston; Michael Berk
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.